• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Soft Tissue Sarcoma - Pipeline Review, H2 2011 - Product Image

Soft Tissue Sarcoma - Pipeline Review, H2 2011

  • ID: 1881611
  • August 2011
  • 71 pages
  • Global Markets Direct

Soft Tissue Sarcoma - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Soft Tissue Sarcoma - Pipeline Review, H2 2011', provides an overview of the Soft Tissue Sarcoma therapeutic pipeline. This report provides information on the therapeutic development for Soft Tissue Sarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma. 'Soft Tissue Sarcoma - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Soft Tissue Sarcoma.
- A review of the Soft Tissue Sarcoma products under development by companies and universities/research READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Soft Tissue Sarcoma Overview
Therapeutics Development
An Overview of Pipeline Products for Soft Tissue Sarcoma
Soft Tissue Sarcoma Therapeutics under Development by Companies
Soft Tissue Sarcoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Soft Tissue Sarcoma Therapeutics - Products under Development by Companies
Soft Tissue Sarcoma Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Soft Tissue Sarcoma Therapeutics Development
Bristol-Myers Squibb Company
Genzyme Corporation
F. Hoffmann-La Roche Ltd.
Amgen Inc.
Eli Lilly and Company
Merck & Co., Inc.
Infinity Pharmaceuticals, Inc.
ZIOPHARM Oncology, Inc.
ImClone Systems Incorporated
Cell Therapeutics, Inc.
Celgene Corporation
MannKind Corporation
AIDA Pharmaceuticals, Inc.
Oncolytics Biotech Inc.
ARQULE, INC
TopoTarget A/S
CytRx Corporation
Threshold Pharmaceuticals, Inc.
MolMed S.p.A.
PharmaMar, S.A.
Epeius Biotechnologies Corporation
Soft Tissue Sarcoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles
Ridaforolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Trabectedin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zymafos + Doxorubicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pazopanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Doxorubicin + Ifosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Docetaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Yondelis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adriamycin + Dacarbazine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adriamycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adriamycin + Vindesine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Etoposide + Ifosfamide + Adriamycin + Regional Hyperthermia + Radiotherapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Etoposide + Ifosfamide + Adriamycin + Radiotherapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Soft Tissue Sarcoma Therapeutics – Drug Profile Updates
Soft Tissue Sarcoma Therapeutics - Discontinued Products
Soft Tissue Sarcoma - Featured News
Aug 01, 2011: ARIAD's Partner Merck Submits Marketing Authorization Application For Ridaforolimus In EU
Jul 06, 2011: CytRx Announces Safe Administration Of High Doses Of Doxorubicin With INNO-206
Jul 06, 2011: GlaxoSmithKline Announces EU And US Regulatory Update On Votrient
Jul 05, 2011: CytRx Receives FDA Orphan Drug Designation For INNO-206 For Treatment Of Soft Tissue Sarcomas
Jun 29, 2011: GP Pharm Presents Conclusions Of Phase II Clinical Trial Of Sarcodoxome For Treatment Of Advanced Soft Tissue Sarcoma
Jun 08, 2011: Morphotek Receives FDA's Orphan Drug Designation For MORAb-004
Jun 06, 2011: Merck And ARIAD Announce Presentation Of Results Of Phase III SUCCEED Trial At ASCO Annual Meeting
Jun 06, 2011: Threshold Pharmaceuticals Presents Promising Results From Phase I/II Clinical Trial Of TH-302 At ASCO Annual Meeting
Jun 04, 2011: GSK Announces Positive Phase III Trial Results Of Pazopanib In Adults With Certain Soft Tissue Sarcomas
Feb 16, 2011: Threshold Signs Agreement With FDA On Special Protocol Assessment For Planned Phase III TH-302 Combination Trial In Advanced Soft Tissue Sarcoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Soft Tissue Sarcoma, H2 2011
Products under Development for Soft Tissue Sarcoma – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Bristol-Myers Squibb Company, 2011
Genzyme Corporation, 2011
F. Hoffmann-La Roche Ltd., 2011
Amgen Inc., 2011
Eli Lilly and Company, 2011
Merck & Co., Inc., 2011
Infinity Pharmaceuticals, Inc., 2011
ZIOPHARM Oncology, Inc., 2011
ImClone Systems Incorporated, 2011
Cell Therapeutics, Inc., 2011
Celgene Corporation, 2011
MannKind Corporation, 2011
AIDA Pharmaceuticals, Inc., 2011
Oncolytics Biotech Inc., 2011
ARQULE, INC, 2011
TopoTarget A/S, 2011
CytRx Corporation, 2011
Threshold Pharmaceuticals, Inc., 2011
MolMed S.p.A., 2011
PharmaMar, S.A., 2011
Epeius Biotechnologies Corporation, 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Soft Tissue Sarcoma Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Soft Tissue Sarcoma, H2 2011
Products under Development for Soft Tissue Sarcoma – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos